Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-304

They have no agreement in place. Big difference to saying they have no interest. If you don't think Novartis is looking at MSB's whole suite of treatments you are being a little naive. Again, I was responding to some fool suggesting MSB was about to go bust after they just announced a $1.7 billion plus partnership deal with Novartis. I take your point though and will be more measured in my wording next time. But SI is clearly talking about a strategic commercial partnerships in "ongoing discussions with large pharmaceutical companies". Novartis is very likely to be one of them.

Silviu has mentioned a partnership in the webcast in relation to CHF. People on here need to take a deep breath and listen to the webcast. This is a positive result. Sure the hospitilzation rates are a dissapointment, but there are treatments out there that reduce that without reducing mortality. MSB reduces mortality rates by 60% and Ischemic heart disease, also called coronary heart disease (CHD), events. You combine it with other "small molecule approaches" as SI puts it.

Whilst the primary endpoint was not met SI called the rates in the second mortality surprising and clearly of far more importance to the FDA.